Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock

The high-growth semaglutide therapy market, which recently saw a massive surge following patent expiries, is now facing a significant inventory crisis. Sluggish sales in May have left wholesalers and stockists sitting on an estimated ₹100 crore worth of excess stock, stalling the momentum of India's obesity therapy sector.

The Sudden Slowdown in Growth

After an explosive start to the year, the ₹2,000-crore obesity therapy market has experienced a notable cooling period. In April, the market witnessed a massive surge, with value growth jumping 50% month-on-month and volumes increasing by 88%. This was largely driven by the flood of cheaper generic semaglutide brands from major pharmaceutical players like Sun Pharma, Torrent, and Dr. Reddy's, following the drug's patent expiry on March 20.

However, the May data tells a different story. According to market research firm Pharmarack, month-on-month value growth slowed down to just 6%, while unit growth decelerated to 12%. This sudden drop has created a supply-demand mismatch that is now impacting the entire pharmaceutical trade channel.

Inventory Overhang and Channel Stagnation

The most pressing concern for industry stakeholders is the massive inventory overhang. Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), noted that stockists and wholesalers are currently holding 50–60 days of GLP-1 (semaglutide) inventory. This is significantly higher than the industry standard of 30–45 days.

Due to this glut, channel partners have effectively hit the pause button on fresh procurement. Stockists are refusing to place new orders with pharmaceutical manufacturers until the existing high-value stocks are liquidated. With the AIOCD representing over 12 lakh chemists and stockists across India, this bottleneck could have wider implications for the organized pharma retail sector.

Regulatory Impact and Competitive Landscape

Industry experts suggest that the moderation in sales might not be purely a demand issue but could be linked to recent regulatory shifts. Government advisories and prescribing restrictions introduced in April stipulate that GLP-1 therapies should only be prescribed by qualified specialists. This move aims to ensure safer usage but may have inadvertently tightened the prescription funnel.

Despite the semaglutide slowdown, other therapies in the GLP-1 receptor agonist class continue to perform well. Mounjaro (tirzepatide), marketed by Eli Lilly, remained the largest selling therapy in the pharma market during May, with sales rising 12% to reach ₹136 crore. This performance contributed to the broader ₹2.5 lakh crore organized pharma retail market, which grew by nearly 11% in May, largely supported by chronic therapies.

Key Takeaways

  • Inventory Crisis: The semaglutide trade channel is burdened with approximately ₹100 crore in excess stock, with wholesalers holding up to 60 days of inventory.
  • Growth Deceleration: After an 88% volume surge in April, May saw growth plummet to 12% in units and 6% in value.
  • Regulatory Influence: New guidelines requiring specialist prescriptions for GLP-1 therapies are believed to be a contributing factor to the cooling demand.